Effect of rapid intravenous infusion on serum concentrations of amphotericin B

Appl Microbiol. 1971 Oct;22(4):615-7. doi: 10.1128/am.22.4.615-617.1971.


The magnitude of the concentrations of amphotericin B produced in serum of patients with systemic mycoses may significantly influence the outcome of therapy with this drug. Since amphotericin B is conventionally administered in intravenous infusions lasting 4 to 6 hr, we asked whether faster infusions of this drug might yield higher serum concentrations without an increase in dose. This question was studied in three patients who received 16 infusions of this drug: eight infusions administered slowly (5 hr) and eight administered rapidly (45 min). Serum concentrations after each rapid infusion were compared with those after a slow infusion administered to the same patient. The mean serum concentration of amphotericin B 1 hr after the rapid infusions (2.02 mug/ml) was significantly higher (P < 0.001) than the mean serum concentration of amphotericin B 1 hr after the slow infusions of this drug (1.18 mug/ml). Mean serum concentrations 18 and 42 hr after rapid infusion remained slightly but not significantly higher than respective mean concentrations after slow infusions. By yielding higher initial serum concentration, rapid intravenous infusion may be therapeutically more effective than slow infusion of amphotericin B. Although rapid infusions caused no more toxicity than did slow infusions, the lack of greater toxicity with rapid infusion of amphotericin B should be further documented prior to extensive clinical application of this procedure.

MeSH terms

  • Amphotericin B / administration & dosage*
  • Amphotericin B / blood*
  • Amphotericin B / toxicity
  • Biological Assay
  • Blood Urea Nitrogen
  • Candida
  • Creatinine / blood
  • Humans
  • Injections, Intravenous
  • Mycoses / blood
  • Mycoses / drug therapy*
  • Time Factors


  • Amphotericin B
  • Creatinine